Vistagen Therapeutics, Inc. (VTGN) KPIs and segments
Close on Nov 13, 2026Market cap $8.01MP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Vistagen Therapeutics's business
Vistagen Therapeutics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
Vistagen Therapeutics's fiscal year ends March 31 — Q3 FY24 = CQ4 2023 (calendar quarter).
| Add to chart | Metric | Q3 FY24 CQ4 2023 | Q2 FY24 CQ3 2023 | Q4 FY23 CQ1 2023 | Q3 FY23 CQ4 2022 | Q2 FY23 CQ3 2022 | Q1 FY23 CQ2 2022 | Q4 FY22 CQ1 2022 | Q3 FY22 CQ4 2021 | Q2 FY22 CQ3 2021 | Q1 FY22 CQ2 2021 | Q3 FY21 CQ4 2020 | Q2 FY21 CQ3 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sublicense($M) | 0.40 | 0.28 | |||||||||||
License($M) | 0.18 | 0.18 | -0.89 | 0.31 | 0.04 | 0.36 | 0.36 | 0.35 | 0.31 | 0.33 | |||
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2024-02-13.
See a number that looks wrong?